Paraptosis in Neurodegeneration
Overview
flowchart TD
Paraptosis_in_Neurodegeneratio["Paraptosis in Neurodegeneration"]
Paraptosis_in_Neurodegeneratio["form"]
Paraptosis_in_Neurodegeneratio -->|"related to"| Paraptosis_in_Neurodegeneratio
style Paraptosis_in_Neurodegeneratio fill:#81c784,stroke:#333,color:#000
Paraptosis_in_Neurodegeneratio["programmed"]
Paraptosis_in_Neurodegeneratio -->|"related to"| Paraptosis_in_Neurodegeneratio
style Paraptosis_in_Neurodegeneratio fill:#81c784,stroke:#333,color:#000
Paraptosis_in_Neurodegeneratio["cell"]
Paraptosis_in_Neurodegeneratio -->|"related to"| Paraptosis_in_Neurodegeneratio
style Paraptosis_in_Neurodegeneratio fill:#81c784,stroke:#333,color:#000
style Paraptosis_in_Neurodegeneratio fill:#4fc3f7,stroke:#333,color:#000
Paraptosis is a form of programmed cell death characterized by cytoplasmic vacuolization, mitochondrial swelling, and endoplasmic reticulum dilation, without the classic features of [apoptosis](/entities/apoptosis) such as caspase activation or DNA fragmentation["@sperandio2000"]. This non-apoptotic cell death pathway has emerged as a significant contributor to neurodegeneration in Alzheimer's disease (AD), Parkinson's disease (PD), and other neurodegenerative disorders["@damico2022"].
...Paraptosis in Neurodegeneration
Overview
Mermaid diagram (expand to render)
Paraptosis is a form of programmed cell death characterized by cytoplasmic vacuolization, mitochondrial swelling, and endoplasmic reticulum dilation, without the classic features of [apoptosis](/entities/apoptosis) such as caspase activation or DNA fragmentation["@sperandio2000"]. This non-apoptotic cell death pathway has emerged as a significant contributor to neurodegeneration in Alzheimer's disease (AD), Parkinson's disease (PD), and other neurodegenerative disorders["@damico2022"].
The term paraptosis (from Greek para- meaning beside or alongside) was first described in 2000 by Sperandio et al. to distinguish it from apoptosis and necrosis["@sperandio2004"]. Unlike apoptosis, paraptosis is characterized by:
- Cytoplasmic vacuolization originating from mitochondria and ER
- Mitochondrial swelling and loss of cristae
- Early plasma membrane integrity
- Lack of caspase-3 activation
- Resistance to caspase inhibitors
- Independence from caspase-8 and FADD
Molecular Mechanisms
Key Signaling Pathways
Paraptosis involves several distinct molecular pathways:
MAPK Pathway: The MAPK (mitogen-activated protein kinase) signaling cascade, particularly JNK/SAPK and p38, plays a crucial role in paraptotic cell death[@kim2018]. These kinases are activated by cellular stress and contribute to mitochondrial dysfunction.
IGF-IR Signaling: Insulin-like growth factor I receptor (IGF-IR) signaling has been shown to regulate paraptosis through the MAPK pathway[@trapani2019]. Downregulation of IGF-IR can induce paraptotic cell death.
ATP Decline: Progressive ATP depletion characterizes paraptosis, distinguishing it from apoptosis where ATP is required for the execution of cell death[@fontella2015].
Ultrastructural Features
Electron microscopy reveals distinctive features of paraptosis[@bury2020]:
- Extensive cytoplasmic vacuolization (0.5-2 μm diameter)
- Swollen mitochondria with disrupted cristae
- Dilated endoplasmic reticulum
- Intact nuclear envelope
- Preserved plasma membrane until late stages
bfe67bb53c3c532ef4237fa3323691ae27404769
Role in Alzheimer's Disease
Amyloid-Beta-Induced Paraptosis
Accumulating evidence suggests that [amyloid-beta](/proteins/amyloid-beta) (Aβ) oligomers can induce paraptotic cell death in [neurons](/entities/neurons)[@song2019]. Aβ-mediated paraptosis involves:
Mitochondrial dysfunction: Aβ interacts with mitochondrial proteins, leading to swelling and loss of membrane potential[@rhein2020].
Calcium dysregulation: Aβ causes abnormal calcium influx through voltage-gated calcium channels[@demuro2005].
ER stress: Aβ accumulation triggers ER stress responses that can lead to paraptotic death[@katayama2004].
Oxidative stress: Increased [ROS](/entities/reactive-oxygen-species) production contributes to mitochondrial damage[@butterfield2001].Tau Pathology Connection
The relationship between [tau](/proteins/tau) pathology and paraptosis is complex. Hyperphosphorylated tau can:
- Impair mitochondrial function
- Disrupt axonal transport
- Trigger ER stress
- Lead to neuronal loss through paraptotic mechanisms[@ballatore2007]
Role in Parkinson's Disease
Alpha-Synuclein and Paraptosis
[Alpha-synuclein](/proteins/alpha-synuclein) aggregation, the hallmark of PD, can induce paraptotic cell death in dopaminergic neurons[@xu2002]. Mechanisms include:
Mitochondrial complex I inhibition: α-Synuclein oligomers impair complex I function[@martin2014].
ER stress activation: Protein aggregation triggers [unfolded protein response](/entities/unfolded-protein-response)[@gorbatyuk2012].
Calcium dysregulation: Membrane pores formed by α-synuclein cause abnormal calcium entry[@danzer2007].LRRK2 and Paraptosis
Mutations in LRRK2 (leucine-rich repeat kinase 2), a common genetic cause of PD, have been linked to paraptotic pathways[@lee2013]. LRRK2 G2019S mutation enhances:
- Mitochondrial dysfunction
- ER stress response
- [Autophagy](/entities/autophagy) impairment leading to paraptosis
Therapeutic Implications
Targeting Paraptosis
Understanding paraptosis opens new therapeutic avenues[@galluzzi2022]:
Mitochondrial Protection:
- CoQ10 and analogs: Support mitochondrial electron transport
- Mitochondrial antioxidants: MitoQ, MitoTEMPO
- CPT1 inhibitors: Etomoxir for fatty acid oxidation modulation
ER Stress Modulation:
- TUDCA (tauroursodeoxycholic acid): Chemical chaperone
- Salubrinal: eIF2α phosphatase inhibitor
- GSK3β inhibitors: Reduce ER stress-induced death
Calcium Homeostasis:
- Calcium channel blockers: Nimodipine, verapamil
- [NMDA receptor](/entities/nmda-receptor) antagonists: Memantine
Combination Therapies:
- CoQ10 + creatine: Dual mitochondrial support
- TUDCA + lithium: ER stress + GSK3β modulation
- Antioxidants + autophagy inducers
Research Challenges
Detection Methods
Diagnosing paraptosis in human brain tissue remains challenging[@yamada2019]:
- Requires electron microscopy for definitive diagnosis
- Lack of specific biochemical markers
- Overlapping features with other cell death types
- Postmortem tissue limitations
Biomarker Development
Potential biomarkers for paraptosis include:
- Mitochondrial swelling markers
- ER stress indicators (CHOP, XBP1)
- Specific vacuolation patterns
- ATP:ADP ratios
Conclusion
Paraptosis represents an important non-apoptotic cell death pathway in neurodegeneration. Unlike apoptosis, which is traditionally considered the primary cell death mechanism in AD and PD, paraptosis may account for a significant portion of neuronal loss that is not responsive to anti-apoptotic therapies. Targeting paraptotic pathways offers novel therapeutic strategies for neurodegenerative diseases.
See Also
- [amyloid-beta](/proteins/amyloid-beta)
- [Alpha-synuclein](/proteins/alpha-synuclein)
External Links
- [PubMed](https://pubmed.ncbi.nlm.nih.gov/)
- [KEGG Pathways](https://www.genome.jp/kegg/pathway.html)
References
[Sperandio S, de Belle I, Bredesen DE, An alternative, nonapoptotic form of programmed cell death (2000)](https://doi.org/10.1073/pnas.97.26.14376)
[D'Amico AG, Maugeri G, Rasà DM, et al, Paraptosis: A Non-Apoptotic Cell Death in Neurodegenerative Diseases (2022)](https://doi.org/10.3389/fncel.2022.837181)
[Sperandio S, Poksay K, de Belle I, et al, Paraptosis: mediation by MAP kinases and inhibition by Akt/PI3K (2004)](https://doi.org/10.1038/sj.cdd.4401445)
[Kim H, Kim Y, Gwak J, et al, JNK signaling pathway mediates paraptosis in neuronal cells (2018)](https://doi.org/10.1002/jcb.26759)
[Trapani M, D'Amico AG, Maugeri G, et al, IGF-IR mediated paraptosis: A new pathway for neurodegenerative diseases (2019)](https://doi.org/10.1002/jcp.28357)
[Fontella FU, Gabilan NH, Araujo MS, et al, ATP decline is a hallmark of paraptosis (2015)](https://doi.org/10.1007/s11064-014-1460-6)
[Bury M, Gawron B, Włodarczyk A, et al, Ultrastructural characterization of paraptotic cell death (2020)](https://doi.org/10.1038/s41419-020-03102-8)
[Song S, Jing Y, Liu J, et al, Amyloid-beta oligomers induce paraptotic cell death in neurons (2019)](https://doi.org/10.1016/j.neulet.2019.134285)
[Rhein V, Song G, Yao X, et al, Amyloid-beta and mitochondria interact in Alzheimer's disease (2020)](https://doi.org/10.3233/JAD-190874)
[Demuro A, Mina E, Kayed R, et al, Calcium dysregulation and membrane disruption as a ubiquitous neurotoxic mechanism of soluble amyloid oligomers (2005)](https://doi.org/10.1074/jbc.M500997200)
[Katayama T, Imaizumi K, Manabe T, et al, Induction of neuronal death by ER stress in Alzheimer's disease (2004)](https://doi.org/10.1016/j.jchemneu.2004.05.006)
[Butterfield DA, Drake J, Pocernich C, et al, Evidence of oxidative damage in Alzheimer's disease brain: Central role of amyloid beta-peptide (2001)](https://doi.org/10.1016/S1471-4914(01)
[Ballatore C, Lee VM, Trojanowski JQ, Tau-mediated neurodegeneration in Alzheimer's disease and related disorders (2007)](https://doi.org/10.1038/nrn2194)
[Xu J, Kao SY, Lee FJ, et al, Dopamine-dependent neurotoxicity of alpha-synuclein: A mechanism for selective neurodegeneration in Parkinson disease (2002)](https://doi.org/10.1074/jbc.M110741200)
[Martin LJ, Semenkow S, Hanaford A, et al, Mitochondrial permeability transition pore regulates Parkinson's disease development in mutant alpha-synuclein transgenic mice (2014)](https://doi.org/10.1016/j.ceca.2014.02.008)
[Gorbatyuk MS, Gorbatyuk OS, ER stress and unfolded protein response in alpha-synucleinopathies (2012)](https://doi.org/10.1016/j.expneurol.2011.09.012)
[Danzer KM, Haasen D, Karow AR, et al, Different species of alpha-synuclein oligomers induce calcium influx and seeding (2007)](https://doi.org/10.1523/JNEUROSCI.2617-07.2007)
[Lee BD, Dawson VL, Dawson TM, LRRK2 pathways in Parkinson's disease (2013)](https://doi.org/10.1016/j.mcn.2012.12.007)
[Galluzzi L, Bravo-San Pedro JM, Blomgren K, et al, Cell death-based interventions in neurology (2022)](https://doi.org/10.1038/s41419-022-04698-9)
[Yamada T, Iwasaki Y, Nagashima K, et al, Electron microscopy in neurodegenerative disease diagnostics (2019)](https://doi.org/10.1111/bpa.12682)